I 

118TH CONGRESS 

2D SESSION H. R. 9220 

To amend the Office of National Drug Control Policy Reauthorization Act 

of 2006 to modify the authority of the Office of National Drug Control 

Policy with respect to the World Anti-Doping Agency, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JULY 30, 2024 

Mr. MOOLENAAR (for himself and Mr. KRISHNAMOORTHI) introduced the 

following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the 

Office of National Drug Control Policy with respect to 

the World Anti-Doping Agency, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Restoring Confidence 

5 in the World Anti-Doping Agency Act of 2024’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 9220 IH

1 SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY 

2 WITH RESPECT TO THE WORLD ANTI-DOPING 

3 AGENCY. 

4 Section 701 of the Office of National Drug Control 

5 Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is 

6 amended— 

7 (1) in subsection (a)— 

8 (A) by amending paragraph (1) to read as 

9 follows: 

10 ‘‘(1) UNITED STATES OLYMPIC AND

11 PARALYMPIC COMMITTEE.—The term ‘United States 

12 Olympic and Paralympic Committee’ means the or13 ganization established by chapter 2205 of title 36, 

14 United States Code.’’; 

15 (B) in paragraph (3), by striking ‘‘(36 

16 U.S.C. 22501(b)(1))’’ and inserting ‘‘(36 

17 U.S.C. 220501(b)(1))’’; 

18 (C) by redesignating paragraphs (1) and 

19 (3) as paragraphs (4) and (1), respectively, and 

20 moving the paragraphs so as to appear in nu21 meric order; and 

22 (D) by inserting after paragraph (2) the 

23 following: 

24 ‘‘(3) INDEPENDENT ATHLETE.—The term 

25 ‘independent athlete’ means an Olympic or 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 9220 IH

1 Paralympic athlete who does not serve, in any capac2 ity— 

3 ‘‘(A) on the International Olympic Com4 mittee; 

5 ‘‘(B) on the International Paralympic 

6 Committee; 

7 ‘‘(C) at an international sports federation 

8 recognized by the International Olympic Com9 mittee or the International Paralympic Com10 mittee; 

11 ‘‘(D) on the United States Olympic and 

12 Paralympic Committee; or 

13 ‘‘(E) at the World Anti-Doping Agency.’’; 

14 (2) in subsection (b)— 

15 (A) by striking ‘‘United States Olympic 

16 Committee’’ each place it appears and inserting 

17 ‘‘United States Olympic and Paralympic Com18 mittee’’; 

19 (B) in paragraph (5), by striking the pe20 riod at the end and inserting ‘‘; and’’; and 

21 (C) by adding at the end the following: 

22 ‘‘(6) carry out responsibilities with respect to 

23 the World Anti-Doping Agency, as described in sub24 section (d).’’; and 

25 (3) by adding at the end the following: 


ssavage on LAPJG3WLY3PROD with BILLS
4 

•HR 9220 IH

1 ‘‘(d) AUTHORITY WITH RESPECT TO THE WORLD

2 ANTI-DOPING AGENCY.— 

3 ‘‘(1) IN GENERAL.—The Office of National 

4 Drug Control Policy, in consultation with the United 

5 States Anti-Doping Agency, the United States Olym6 pic and Paralympic Committee, and the Team USA 

7 Athletes’ Commission, shall— 

8 ‘‘(A) use all available tools to ensure 

9 that— 

10 ‘‘(i) the World Anti-Doping Agency 

11 has a credible and independent governance 

12 model that provides for fair representation 

13 of the United States; 

14 ‘‘(ii) the World Anti-Doping Agency 

15 fully implements all governance reforms, 

16 including a proper conflict-of-interest pol17 icy for all members of the Executive Com18 mittee, the Foundation Board, and all rel19 evant expert advisory groups, standing 

20 committees, permanent special committees, 

21 and working groups of the World Anti22 Doping Agency; and 

23 ‘‘(iii) independent athletes from the 

24 United States and other democratic coun25 tries, or representatives of such athletes, 


ssavage on LAPJG3WLY3PROD with BILLS
5 

•HR 9220 IH

1 have decision-making roles on the Execu2 tive Committee and the Foundation Board, 

3 and in all relevant expert advisory groups, 

4 standing committees, permanent special 

5 committees, and working groups, of the 

6 World Anti-Doping Agency; 

7 ‘‘(B) demonstrate leadership within the 

8 global community; 

9 ‘‘(C) have strict standards that work to10 ward countering doping in every form, including 

11 by countering systemic fraud through doping 

12 involving— 

13 ‘‘(i) governmental law enforcement, 

14 intelligence, or anti-doping institutions; 

15 ‘‘(ii) sporting organizations; or 

16 ‘‘(iii) athlete support personnel; and 

17 ‘‘(D) work collaboratively with democratic 

18 countries. 

19 ‘‘(2) DETERMINATION.— 

20 ‘‘(A) IN GENERAL.—Not later than 90 

21 days after the date of the enactment of this 

22 subsection, the Office of National Drug Control 

23 Policy, in consultation with the United States 

24 Anti-Doping Agency, the United States Olympic 

25 and Paralympic Committee, and the Team USA 


ssavage on LAPJG3WLY3PROD with BILLS
6 

•HR 9220 IH

1 Athletes’ Commission, shall make a determina2 tion as to whether the World Anti-Doping 

3 Agency— 

4 ‘‘(i) has a credible and independent 

5 governance model that provides for fair 

6 representation of the United States; 

7 ‘‘(ii) fully implements all governance 

8 reforms, including a proper conflict-of-in9 terest policy described in paragraph 

10 (1)(A)(ii); and 

11 ‘‘(iii) allows independent athletes from 

12 the United States and other democratic 

13 countries, or representatives of such ath14 letes, to have decision-making roles on the 

15 Executive Committee and the Foundation 

16 Board, and in all relevant expert advisory 

17 groups, standing committees, permanent 

18 special committees, and working groups, of 

19 the World Anti-Doping Agency. 

20 ‘‘(B) ACCOUNTABILITY.—In the case of a 

21 determination under subparagraph (A) that the 

22 World Anti-Doping Agency does not have such 

23 a governance model, has not fully implemented 

24 such governance reforms, or has not allowed de25 cision-making roles described in clause (iii) of 


ssavage on LAPJG3WLY3PROD with BILLS
7 

•HR 9220 IH

1 that subparagraph, the Office of National Drug 

2 Control Policy, in consultation with the United 

3 States Anti-Doping Agency, the United States 

4 Olympic and Paralympic Committee, and the 

5 Team USA Athletes’ Commission, shall— 

6 ‘‘(i) use all available tools to ensure 

7 that the United States has fair representa8 tion in the World Anti-Doping Agency, in9 cluding— 

10 ‘‘(I) on the Executive Committee; 

11 ‘‘(II) on the Foundation Board; 

12 and 

13 ‘‘(III) in all relevant expert advi14 sory groups, standing committees, 

15 permanent special committees, and 

16 working groups of the World Anti17 Doping Agency; and 

18 ‘‘(ii) not later than 180 days after the 

19 date on which the determination under 

20 subparagraph (A) is made, issue a report 

21 that describes the barriers to participation 

22 and fair representation of the United 

23 States on the Executive Committee, the 

24 Foundation Board, and all relevant expert 

25 advisory groups, standing committees, perVerDate Sep 11 2014 01:06 Aug 30, 2024 Jkt 049200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\H9220.IH H9220

ssavage on LAPJG3WLY3PROD with BILLS
8 

•HR 9220 IH

1 manent special committees, and working 

2 groups of the World Anti-Doping Agency. 

3 ‘‘(3) VOLUNTARY NONPAYMENT OF DUES.— 

4 ‘‘(A) IN GENERAL.—In the case of a deter5 mination under paragraph (2)(A) that the 

6 World Anti-Doping Agency does not have a gov7 ernance model that provides for fair representa8 tion of the United States, has not fully imple9 mented governance reforms, or has not allowed 

10 decision-making roles described in clause (iii) of 

11 that subparagraph, the Office of National Drug 

12 Control Policy, in consultation with the appro13 priate committees of Congress, may voluntarily 

14 withhold up to the full amount of membership 

15 dues to the World Anti-Doping Agency. 

16 ‘‘(B) APPROPRIATE COMMITTEES OF CON17 GRESS DEFINED.—In this paragraph, the term 

18 ‘appropriate committees of Congress’ means— 

19 ‘‘(i) the Subcommittee on Consumer 

20 Protection, Product Safety, and Data Se21 curity of the Committee on Commerce, 

22 Science, and Transportation of the Senate 

23 (or a successor subcommittee); 

24 ‘‘(ii) the Subcommittee on Financial 

25 Services and General Government of the 


ssavage on LAPJG3WLY3PROD with BILLS
9 

•HR 9220 IH

1 Committee on Appropriations of the Sen2 ate (or a successor subcommittee); 

3 ‘‘(iii) the Subcommittee on Oversight 

4 and Investigations of the Committee on 

5 Energy and Commerce of the House of 

6 Representatives (or a successor sub7 committee); and 

8 ‘‘(iv) the Subcommittee on Financial 

9 Services and General Government of the 

10 Committee on Appropriations of the House 

11 of Representatives (or a successor sub12 committee). 

13 ‘‘(4) SPENDING PLAN.—Not later than 30 days 

14 before the Office of National Drug Control Policy 

15 obligates funds to the World Anti-Doping Agency, 

16 the Office of National Drug Control Policy shall sub17 mit to the Committee on Appropriations of the Sen18 ate and the Committee on Appropriations of the 

19 House of Representatives a spending plan and expla20 nation of proposed uses of such funds.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS